Search results
Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. This guideline provides strategies for open, nonjudgmental communication between clinicians and adults with cancer about the use of cannabis and/or cannabinoids.
13 mar 2024 · (1) How should clinicians and adults with cancer communicate about cannabis and/or cannabinoids? (2) Does use of cannabis and/or cannabinoids by adults improve cancer-directed treatment? (3) Does use of cannabis and/or cannabinoids by adults with cancer reduce treatment-related toxicities, palliate cancer symptoms, or improve quality of life (QOL)?
22 lut 2022 · To assess the efficacy, tolerability and safety of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer.
13 mar 2024 · In 2024, ASCO published a guideline on the use of cannabis and cannabinoids by adults with cancer. 1 The guideline provides strategies for open, nonjudgmental communication and also discusses evidence regarding cannabis and cannabinoids as cancer-directed therapy and for managing cancer symptoms and treatment side effects.
This clinical practice guideline addresses three clinical questions in adults with cancer: 1. How should clinicians and adults with cancer communicate about cannabis and/or cannabinoids? 2. Does use of cannabis and/or cannabinoids by adults improve cancer-directed treatment? 3.
Cannabis and/or cannabinoids are one of several pharmacologic options for adults with cancer experiencing refractory nausea and vomiting despite optimal prophylaxis. For such individuals, the 2020 ASCO antiemetics guideline 2 recommends
5 cze 2023 · We found five RCTs assessing oromucosal nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) or THC alone involving 1539 participants with moderate or severe pain despite opioid therapy. The double-blind periods of the RCTs ranged between two and five weeks.
